AlloVir Inc. (NASDAQ: ALVR) stock fell -14.34% on Monday to $2.15 against a previous-day closing price of $2.51. With 1.89 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.96 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.5300 whereas the lowest price it dropped to was $2.1000. The 52-week range on ALVR shows that it touched its highest point at $10.29 and its lowest point at $2.42 during that stretch. It currently has a 1-year price target of $19.75. Beta for the stock currently stands at 0.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALVR was down-trending over the past week, with a drop of -24.30%, but this was down by -12.96% over a month. Three-month performance dropped to -59.43% while six-month performance fell -52.75%. The stock lost -74.37% in the past year, while it has lost -58.09% so far this year. A look at the trailing 12-month EPS for ALVR yields -1.82 with Next year EPS estimates of -1.63. For the next quarter, that number is -0.42. This implies an EPS growth rate of 19.60% for this year and 5.80% for next year.
Float and Shares Shorts:
At present, 94.63 million ALVR shares are outstanding with a float of 57.87 million shares on hand for trading. On Aug 30, 2023, short shares totaled 8.31 million, which was 7.30% higher than short shares on Jul 30, 2023. In addition to Mr. David L. Hallal as the firm’s Exec. Chairman, Dr. Diana M. Brainard M.D. serves as its CEO & Director.
Through their ownership of 35.14% of ALVR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 50.59% of ALVR, in contrast to 29.28% held by mutual funds. Shares owned by individuals account for 20.19%. As the largest shareholder in ALVR with 8.36% of the stake, Fidelity Management & Research Co holds 9,521,542 shares worth 9,521,542. A second-largest stockholder of ALVR, Wasatch Advisors, Inc., holds 6,644,113 shares, controlling over 5.84% of the firm’s shares. Invus Public Equities Advisors LL is the third largest shareholder in ALVR, holding 6,597,167 shares or 5.79% stake. With a 2.38% stake in ALVR, the Fidelity Growth Company Fund is the largest stakeholder. A total of 2,708,706 shares are owned by the mutual fund manager. The Wasatch Small Cap Growth Fund, which owns about 2.16% of ALVR stock, is the second-largest Mutual Fund holder. It holds 2,455,450 shares valued at 7.69 million. ACAP Strategic Fund holds 2.02% of the stake in ALVR, owning 2,297,288 shares worth 7.19 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ALVR reported revenue of $0.00 and operating income of -$44.62M. The EBITDA in the recently reported quarter was -$44.54M and diluted EPS was -$0.69.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALVR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALVR analysts setting a high price target of $27.00 and a low target of $15.00, the average target price over the next 12 months is $19.75. Based on these targets, ALVR could surge 1155.81% to reach the target high and rise by 597.67% to reach the target low. Reaching the average price target will result in a growth of 818.6% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded ALVR stock several times over the past three months with 2 Buys and 10 Sells. In these transactions, 3,077,870 shares were bought while 36,988 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has risen to 43 over the past year. The total number of shares bought during that period was 4,033,716 while 323,611 shares were sold.